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Abstract
Background An early invasive strategy (EIS) is rec-
ommended in high-risk patients with non-ST-eleva-
tion acute coronary syndrome (NSTE-ACS), defined
as coronary angiography (CAG), within 24h of ad-
mission. The aim of the present study is to investi-
gate guideline adherence, patient characteristics as-
sociated with timing of the intervention and clinical
outcome.
Methods In a prospective registry, the use and tim-
ing of CAG and the characteristics and clinical out-
come associated with timing were evaluated in high-
risk ACS patients. The outcome of early versus delayed
invasive strategy (DIS) was compared.
Results Between 2006 and 2014, 2,299 high-risk NSTE-
ACS patients were included. The use of CAG increased
from 77% in 2006 to 90% in 2014 (p trend <0.001) to-
E. A. Badings () · A. Van Der Sluis
Department of Cardiology, Deventer Hospital, Deventer, The
Netherlands
e.badings@dz.nl
R. S. Hermanides · J. H. E. Dambrink · A. T. M. Gosselink ·
E. Kedhi · J. P. Ottervanger · V. Roolvink · W. S. Remkes ·
H. Suryapranata · A. W. J. van’t Hof
Isala Heart Centre, Zwolle, The Netherlands
E. van’t Riet
Teaching Hospital, Deventer Hospital, Deventer, The
Netherlands
H. Suryapranata
Department of Cardiology, Radboud University Medical
Centre, Nijmegen, The Netherlands
A. W. J. van’t Hof
Department of Cardiology, Maastricht UMC+, Maastricht,
The Netherlands
gether with a decrease of median time to CAG from
23.3 to 14.5h (p trend <0.001) and an increase of pa-
tients undergoing EIS from 50 to 60% (p trend= 0.002).
Patient factors independently related to DIS were
higher GRACE risk score, higher age and the pres-
ence of comorbidities. No difference was found in
incidence of mortality, reinfarction or bleeding at 30-
day follow-up. All-cause mortality at 1-year follow-up
was 4.1% vs 7.0% in EIS and DIS respectively (hazard
ratio 1.67, 95% confidence interval 1.12–2.49) but was
comparable after adjustment for confounding factors.
Conclusion The percentage of high-risk NSTE-ACS pa-
tients undergoing CAG and EIS has increased in the
last decade. In contrast to the guidelines, patients
with a higher risk profile are less likely to undergo
EIS. However, no difference in outcome after 30 days
and 1 year was found after multivariate adjustment
for this higher risk.
What’s new?
 For high-risk patients with non-ST-elevation
acute coronary syndrome, guidelines recom-
mend early invasive treatment (coronary an-
giography within 24h of admission), but only
60% of patients are treated this way in clinical
practice.
 In contrast to the guidelines, patients with
a higher risk profile are less likely to undergo
early invasive treatment.
 No difference in outcome was found between
early and late invasive treatment at 30 days and
1 year following multivariate adjustment for risk
factors.
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Background
In recent decades, numerous randomised clinical tri-
als have been performed to investigate the optimal
timing of intervention in patients with non-ST-ele-
vation acute coronary syndrome (NSTE-ACS). The re-
sults of these studies have been summarised in several
meta-analyses [1–7]. In summary, earlier intervention
showed no significant difference in mortality or re-
infarction but only a reduction in the incidence of
refractory ischaemia and in duration of hospital stay.
A pre-specified subgroup analysis of the largest
trial, TIMACS [8], showed a statistically significant
reduction of 35% in the combined endpoint of death,
myocardial infarction, and stroke with an early in-
vasive treatment strategy in patients with a Global
Registry of Acute Coronary Events (GRACE) risk score
of more than 140. Based on the findings of this other-
wise negative trial, current guidelines [9] recommend
that the timing of angiography be guided by indi-
vidual risk stratification. An early invasive treatment
strategy is recommended in patients with at least one
of the following high-risk factors: rise or fall in car-
diac troponin, dynamic ST- or T-wave changes and
GRACE risk score >140. This treatment strategy is
defined as coronary angiography performed within
24h of hospital admission.
The aim of the present study is to investigate to
what extent these guidelines are followed in clinical
practice in patients hospitalised with a NSTE-ACS and
at least one high-risk criterion. The application of
early and delayed invasive treatment and the associ-
ation between patient characteristics and the timing
of invasive treatment were investigated. In addition,
clinical outcome at 30-day and 1-year follow-up was
compared between early and delayed invasive strat-
egy.
Methods
The BAMI (Dutch abbreviation for ‘Treatment of
Acute Myocardial Ischaemia’) registry is a database
with all consecutive patients hospitalised with an
acute coronary syndrome (ACS) at Isala, a large, non-
academic hospital with 24/7 interventional cardiology
facilities in Zwolle, the Netherlands. For the present
study, we selected patients hospitalised with NSTE-
ACS between 2006 and 2014 with at least one high-risk
criterion (rise or fall in cardiac troponin compatible
with myocardial infarction, dynamic ST- or T-wave
changes and GRACE risk score >140) but without
very-high-risk criteria. Patients referred from non-
interventional hospitals were excluded.
The rate of patients undergoing coronary angiog-
raphy and the time between hospitalisation and the
start of coronary angiography was calculated and
compared over the years. Based on timing, patients
were divided into two groups: those undergoing early
invasive treatment (coronary angiography performed
within 24h after hospitalisation) and those under-
going delayed invasive treatment (angiography more
than 24h after admission).
Clinical, demographic and procedural characteris-
tics were prospectively collected and compared be-
tween the two groups as well as all-cause mortality,
reinfarction and bleeding events within 30 days of
hospitalisation. All-cause mortality after 1 year was
investigated by consulting the Dutch Municipal Per-
sonal Records Database of the last known residence
of the patient.
Definitions of myocardial infarction were in accor-
dance with the most recent universal definitions [10].
Bleeding events at 30-day follow-up were defined as
clinically overt bleeding with a drop in haemoglobin
level of at least 2mmol/l or a blood transfusion of
9198 ACS
3580 NSTE-ACS
2673
2299 high risk
1805 CAG
972 early  
invasive
833 delayed 
invasive
5618 STEMI
907 referred from 
other hospitals
87 very high risk
287 intermediate 
or low risk
494 no CAG
Fig. 1 Flowchart of selection of patients with high-risk
NSTE-ACS from the BAMI registry (CAG coronary angiogra-
phy, NSTE-ACS non-ST-elevation acute coronary syndrome,
STEMI ST-elevation myocardial infarction)
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Fig. 2 Box and whiskers
plot of time in minutes from
hospitalisation to coronary
angiography. Horizontal line
depicts 1,440min (24h).
Boxes depict median and
25th and 75th percentiles,
whiskers 5th and 95th per-
centiles (CAG coronary an-
giography, min minutes)
2 units of packed cells or more. Cut-off values for
cardiac enzymes changed over time. Until February
2011, a troponin T level of 0.1ng/ml was considered
to be elevated. After this date, a high-sensitivity tro-
ponin assay was usedwith a cut-off value of 0.014ng/l.
Reference values for creatine kinase (CK) and CK-MB
remained stable during the study with cut-off points
for CK of 200U/l (men) and 170U/l (women) and for
CK-MB of 24U/l or 6% of CK if CK >200U/l.
Statistical analysis
Continuous variables are presented as means and
standard deviation if normally distributed, otherwise
as medians with 25th and 75th percentiles. Categor-
ical variables are presented as percentages. A graph
with timing of coronary angiography over time was
constructed. Comparison of continuous variables in
patients receiving early or delayed invasive angiog-
raphy were performed by independent samples t-
test or ANOVA if normally distributed (and after log
transformation, if necessary) or Kruskal-Wallis test.
For categorical data, the χ2 test was used. Multivari-
ate logistic regression analysis was used to identify
patient factors independently related to timing of
angiography. The outcome of an early and delayed
treatment strategy was compared calculating hazard
ratios using Cox regression analysis for total mortality,
reinfarction and bleeding events. Determinants which
affected the regression coefficient of the association
between treatment strategy and outcome with more
than 10%, were added to the multivariate regression
model. Furthermore, hazard ratios were calculated
adjusted for GRACE risk score, a validated predictor of
adverse cardiovascular events after ACS [11]. A two-
sided p-value <0.05 was considered statistically sig-
nificant. Statistical analysis was performed with IBM
SPSS version 22.0 (IBM Corp, New York, NY, USA).
Results
Patients
Between January 2006 and December 2014, 9,198 con-
secutive patients with a discharge diagnosis of ACS
were enrolled in the BAMI registry. In Fig. 1, the
flow chart is shown. For the current study, 3,580 pa-
tients with a NSTE-ACS were included, of whom 2,673
were hospitalised directly at Isala. In 2,299 patients
at least one high-risk and no very-high-risk criterion
was present and 1,805 of them underwent coronary
angiography. The 494 high-risk patients that did not
undergo angiography were older, more often female
and median age, GRACE risk score, Killip class as well
as the percentage with comorbidities and renal dys-
function were significantly higher.
Temporal trends in use of angiography
The percentage of patients with NSTE-ACS and at least
one high-risk criterion that underwent coronary an-
giography increased gradually from about 77% in 2006
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Table 1 Demographic, clinical and procedural characteristics of patients undergoing early (<24h) or delayed invasive treat-
ment strategy (>24h after hospitalisation)
All Treatment strategy p-value
Early Delayed
n (%) 1,805 972 (53.9) 833 (46.1) –
Time admission-angiography min (median
Q1–3)
1,330 (360–3,457) 406 (209–940) 4,008 (2,436–6,723) –
Demographics
Male gender (%) 68.1 69.1 67.0 0.352
Age (years; mean, SD) 66.8 (12.1) 65.0 (12.2) 68.9 (11.7) <0.001
Medical history (%)
Diabetes 20.6 16.8 25.2 <0.001
Smoking 31.0 33.2 28.5 0.032
Hypercholesterolaemia 34.1 33.2 35.2 0.366
Positive family history 38.4 40.6 35.8 0.035
Previous MI 17.2 13.9 21.1 <0.001
Previous PCI 18.0 14.5 22.0 <0.001
Previous CABG 12.4 9.4 15.8 <0.001
Previous CVA 3.6 2.8 4.5 0.060
Hypertension 55.0 50.3 60.4 <0.001
Admission parameters
Elevated cardiac enzymes (%) 93.8 92.6 95.2 0.023
GRACE risk score >140a (%) 37.0 32.5 42.1 <0.001
ST segment deviation >0.5mm (%) 42.4 47.6 36.4 <0.001
CK-max< 24 (umol/l; median, SD) 168 (100–347) 190 (108–425) 146 (92–250) <0.001
GRACE scorea (median, Q1–3) 130 (109–155) 126 (105–150) 135 (112–163) <0.001
Killip class> 1 (%) 27.7 26.4 29.2 0.175
Creatinine>median (%) 51.0 47.7 54.9 0.003
Vessel disease (%) <0.001
0 11.6 9.3 14.2 –
1 30.4 33.2 27.2 –
>1 58.0 57.5 58.6 –
Treatment <0.001
Conservative (%) 22.6 17.7 28.5 –
CABG performed (%) 18.2 18.0 18.5 –
PCI performed (%) 59.2 64.3 53.1 –
Hospitalisation weekend (%) 26.3 23.0 30.2 0.001
Medication before angiography
ASA (%) 81.2 85.3 76.4 <0.001
Clopidogrel (%) 88.6 91.9 85.0 0.488
G2b3a inhibitor (%) 16.9 22.1 10.9 <0.001
Heparin (%) 63.7 68.9 57.7 <0.001
to 90% in 2014 (p trend< 0.001). Median time from
admission to angiography decreased from 1,400 to
870min (23.3 to 14.5h) over the years (p<0.001 anal-
ysis of variance, after log transformation, Fig. 2). The
proportion of patients undergoing early invasive treat-
ment increased from about 50% in 2006 to 60% in 2014
(p trend= 0.002).
Timing of coronary angiography
In 972 of 1,805 high-risk NSTE-ACS patients (53.9%)
coronary angiography was performed within 24h of
hospitalisation. Demographic, clinical and procedu-
ral characteristics are shown in Tab. 1. Patients in
the delayed treatment group were significantly older
and the percentage of patients with diabetes, family
and personal history of cardiovascular disease was
higher. GRACE risk score, percentages of patients
with positive biomarkers at hospitalisation, Killip class
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Table 1 (Continued)
All Treatment strategy p-value
Early Delayed
At discharge (%)
ACE-I (%) 59.0 60.6 57.2 0.159
AII blockers (%) 11.8 9.3 14.6 0.001
RAS inhibitionb (%) 70.7 70.8 70.6 0.926
ASA (%) 83.1 86.2 79.6 <0.001
Beta blockers (%) 91.3 91.1 91.6 0.742
Calcium antagonist (%) 20.8 17.1 25.0 <0.001
P2Y12 inhibitor (%) 70.7 72.6 68.5 0.055
Coumarin (%) 17.5 12.1 23.5 <0.001
Nitrate (%) 18.0 12.3 24.5 <0.001
Statin (%) 85.0 85.1 84.8 0.842
AII angiotensin II, ACE-I angiotensin converting enzyme inhibitor, ASA acetylsalicylic acid, CABG coronary arterial bypass grafting, CK creatine kinase,
CVA cerebrovascular accident, GRACE Global Registry of Acute Coronary Events, MI myocardial infarction, PTCA percutaneous transluminal coronary angioplasty,
Q quartile, RAS renin angiotensin system, SD standard deviation
aBased on less than 90% of patients
bACE-I and/or AII blockers
>1 and CK above median were also higher in this
group. Among the early-treated patients, a higher
number with an ST deviation >0.5mm on admission
ECG were seen. Of the patients hospitalised at week-
ends, 56% underwent angiography after more than
24h, compared to 47% of those admitted onweek days
(p< 0.001) with a median time from hospitalisation to
angiography of 36 versus 21.6h (p= 0.07, after loga-
rithmic transformation).
Significantly more patients in the early invasive
treatment group were treated with anti-thrombotics
and anti-coagulants before angiography and under-
went a percutaneous coronary intervention (PCI). The
percentages of patients undergoing coronary artery
bypass graft (CABG) were comparable. Discharge
medication differed in the prescription of acetyl-
salicylic acid (more often in the early group) and
coumarins, calcium blockers and nitrates (more of-
ten in the delayed group). The use of beta blockers,
RAS blockers and P2Y12 inhibitors was comparable.
Factors independently related to delayed angiography
Table 2 Multivariate regression analysis of factors in-
dependently related with timing of coronary angiography
(odds ratio of delayed versus early angiography)
OR 95% CI p-value
Age (per year) 1.024 1.015–1.034 <0.001
ST segment devia-
tion> 0.5mm
0.538 0.435–0.667 <0.001
Year of inclusion 0.913 0.872–0.956 <0.001
Hypertension 1.303 1.051–1.615 0.016
Diabetes 1.419 1.090–1.848 0.009
Previous PCI 1.386 1.042–1.845 0.025
Previous CABG 1.389 0.997–1.936 0.052
Hospitalisation at weekend 1.702 1.345–2.153 <0.001
CABG coronary artery bypass graft, CI confidence interval, OR odds ratio,
PCI percutaneous coronary intervention
are shown in Tab. 2 and include higher age, absence
of ST-segment deviation >0.5mm, history of hyper-
tension, diabetes, a previous PCI or CABG as well
as hospitalisation at weekends. Patients that were
included in the registry earlier were more likely to
undergo delayed angiography.
Outcome
All-cause mortality at 30-day follow-up was 1.3% in
the early and 1.4% in the delayed treatment groups
(hazard ratio (HR) 1.07, 95% confidence interval (CI)
0.49–2.35, Table 3). This difference was not statis-
tically significant. Recurrent myocardial infarction
occurred in 0.8% of both groups (HR 1.02, 95% CI
0.37–2.81). The incidence of total bleeding events
was 18.2% in the early and 16.7% (HR 0.89, 95% CI
0.71–1.11) in the delayed treatment group and of
non-CABG related bleeding 3.4% and 3.2%, respec-
tively (HR 0.92, 95% CI 0.55–1.53). At 1-year follow-
up, all-cause mortality was significantly higher in the
delayed treatment group (7.0 vs 4.1%, HR 1.67, 95%
CI 1.12–2.49) but after adjustment for GRACE risk
score and other confounding factors, this difference
was no longer statistically significant. The prognosis
of high-risk patients that did not undergo coronary
angiography was significantly worse, with mortality
of 20.5% and 42.2% at 30-day and 1-year follow-up
respectively.
Discussion
In this prospective registry of 2,299 high-risk NSTE-
ACS patients hospitalised between 2006 and 2014, the
percentage of patients that underwent coronary an-
giography increased from 77 to 90% between 2006 and
2014. Concurrently, median time from admission to
angiography decreased from 23.3 to 14.5h with an in-
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Table 3 Incidence, HR, 95% CI and p-value for outcome parameters in delayed versus early intervention with univariate
analysis and adjusted for confounding factors
Early intervention Delayed intervention HR 95% CI p-value
All-cause mortality 30-day follow-up
Incidence (%) 1.3 1.4 1.07 0.49–2.35 0.86
– Adjusted for GRACE risk score 0.68 0.29–1.62 0.39
– Adjusted for serum creatinine, age, ST deviation and previous CABG 0.74 0.31–1.73 0.48
Reinfarction 30-day follow-up
Incidence (%) 0.8 0.8 1.02 0.37–2.81 0.97
– Adjusted for GRACE risk score 1.19 0.40–3.57 0.75
– Adjusted for diabetes, previous MI and age 0.66 0.23–1.88 0.44
Total bleeding events 30-day follow-up
Incidence (%) 18.2 16.7 0.89 0.71–1.11 0.28
– Adjusted for GRACE risk score 0.86 0.67–1.10 0.24
– Adjusted for age, ST deviation, previous CABG, max. CK 0.88 0.69–1.12 0.29
Non-CABG-related bleeding events 30-day follow-up
Incidence (%) 3.4 3.2 0.92 0.55–1.53 0.75
– Adjusted for GRACE risk score 0.73 0.41–1.27 0.26
– Adjusted for age, previous PCI and ST deviation 0.85 0.50–1.43 0.53
All-cause mortality 1-year follow-up
Incidence (%) 4.1 7.0 1.67 1.12–2.49 0.01
– Adjusted for GRACE risk score 0.71 0.44–1.13 0.15
– Adjusted for age, diabetes, previous CABG 0.83 0.55–1.25 0.37
CABG coronary arterial bypass grafting, CI confidence interval, CK creatine kinase, GRACE Global Registry of Acute Coronary Syndromes, HR hazard ratio,
MI myocardial infarction, PCI percutaneous coronary intervention
crease from 50 to 60% of patients being treated within
24h of admission and fulfilling the criteria of early in-
vasive treatment used in the guidelines. This reflects
more stringent adherence to the guidelines concern-
ing the timing of treatment in this patient category.
These changes over time are in line with findings
in other registries [12–18]. In general, use of angiog-
raphy and PCI increased over time, although differ-
ences were seen between geographical regions and
age groups. This rising trend in adherence to guide-
line treatment recommendations is associated with
improved outcome such as lower mortality and fewer
hospitalisations for heart failure [16–18].
Patient factors independently related to delayed
coronary angiography in this study were higher
GRACE score, higher age and the presence of co-
morbidities such as hypertension, diabetes and es-
tablished cardiovascular disease. This inverse rela-
tionship between risk profile and the use of invasive
treatment has been found in many other observa-
tional studies [14, 19–22]. In contrast to the guidelines,
which advise an early invasive strategy especially in
higher-risk NSTE-ACS patients, this is obviously not
applied in daily practice. The GRACE [15, 19], Cana-
dian ACS [14, 20] and CRUSADE [21] registries found
that invasive treatment was paradoxically more often
applied in lower-risk patients. Waiting time for an-
giography was also longer in higher-risk patients [22].
Despite the more stringent guidelines concerning the
timing of intervention in NSTE-ACS patients, our re-
sults are similar to those found in previous studies.
Likewise, aggressive anti-thrombotic pharmacother-
apy was prescribed more often in low-risk patients
in our study, compatible with findings in registries in
Canada and the United States [14, 20]. However, the
decreased prescription of GPIIb/IIIa receptor blockers
in the delayed group could be explained by the lower
rate of percutaneous interventions.
A possible explanation for this so-called ‘risk-para-
dox’ is that cardiologists have more safety concerns
with early invasive treatment in older patients pre-
senting with NSTE-ACS. Although invasive treatment
is associated with significant benefits independent of
age [23–25], age appeared to be underrated as a risk
factor in deciding whether or not to perform angiog-
raphy [26, 27]. However, it is also possible that other
valid reasons led to a reluctance to perform invasive
procedures in older patients, such as functional sta-
tus, patient’s preference and frailty, which has been
shown to be related to a worse outcome in NSTE-ACS
[28].
Patients hospitalised at weekends were more likely
to receive angiography after more than 24h. Although
this is a well-known phenomenon, this was not seen
in other registries [22, 29] and is probably related to
logistics and planning of angiography.
Although patients in the delayed treatment group
had a higher risk profile, no differences were found in
the incidence ofmortality, reinfarction and bleeding at
30-day follow-up, either with univariate analysis and
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when adjusted for confounding factors. Although it
should always be taken into account that unidentified
confounders may be present, this suggests that the
timing of treatment does not impact on clinical out-
come to a great extent. The higher all-cause mortality
at 1-year follow-up in the delayed treatment group
was driven by higher age and other risk factors and
was no longer present after correction by multivari-
ate logistic regression. Post hoc subgroup analysis of
patients with a GRACE risk score >140 showed no sig-
nificant differences in outcome with early or delayed
intervention.
Our study has the following limitations. First of
all, it is possible that important predictive factors
associated with the timing of intervention have not
been taken into account in our study: these include
frailty, patient preference and comorbidity. Next, as
this was a single-centre study, the generalisability of
our findings to high-risk NSTE-ACS patients in gen-
eral is questionable because local procedures may
differ between hospitals and regions. However, simi-
lar results were found by previous multicentre studies
[14, 19–22]. Also, we excluded patients who were
initially hospitalised in non-interventional hospitals
to avoid bias by logistic factors. The characteristics
of this group of patients might differ from those hos-
pitalised directly at an interventional centre. The
outcome results in the delayed treatment group may
be too favourable due to survival bias; the effect of
patients who die early after hospitalisation is miss-
ing. Finally, results of observational, non-randomised
studies should always be interpreted with caution
because unidentified confounders may be present.
Conclusions
The percentage of high-risk NSTE-ACS patients un-
dergoing coronary angiography has increased in the
last decade, together with a decrease in time from ad-
mission to angiography. In contrast to the guidelines,
patients with a higher risk profile were less likely to
receive an early invasive treatment strategy. However,
after adjustment for this higher risk, no difference in
outcome after 30 days and 1 year was found.
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